

|   |                                      |   |  |
|---|--------------------------------------|---|--|
| <b>Examiner-Initiated Interview Summary</b> | <b>Application No.</b><br>09/807,657 | <b>Applicant(s)</b><br>GARCON, NATHALIE |  |
|   | <b>Examiner</b><br>Zachariah Lucas   | <b>Art Unit</b><br>1648                 |  |

**All Participants:**

(1) Zachariah Lucas.

(2) Reid S. Willis.

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_.

(4) \_\_\_\_\_.

**Date of Interview:** 8 April 2005

**Time:** \_\_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

**Exhibit Shown or Demonstrated:** ☐ Yes ☒ No

If Yes, provide a brief description:

**Part I.**

**Rejection(s) discussed:**

NA

**Claims discussed:**

76, 109, 141

**Prior art documents discussed:**

NA

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*See Continuation Sheet*

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
 (Examiner/SPE Signature)

\_\_\_\_\_  
 (Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner indicated that the claims were mostly in condition for allowance. However, the Examiner noted that claims 76 and 109 each depended from a cancelled claim. The Examiner also noted that claim 141, which purported to set forth a list of immunostimulatory cytokines, included non-cytokines in the list. The Examiner indicated that the claims would be allowable if claims 76 and 109 were cancelled, and claim 141 was amended such that it no longer misidentified the group of immunostimulants listed. The Applicant indicated that an Examiner's Amendment cancelling claims 76 and 109, and amending claim 141 such that it recited only GM-CSF and IL-1 would be acceptable. .